{"id":48464,"date":"2025-11-17T19:26:37","date_gmt":"2025-11-17T11:26:37","guid":{"rendered":"https:\/\/flcube.com\/?p=48464"},"modified":"2025-11-17T19:26:38","modified_gmt":"2025-11-17T11:26:38","slug":"zhejiang-jianfeng-group-secures-nmpa-approval-for-jfan%e2%80%911001-vinorelbine-combination-in-advanced-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48464","title":{"rendered":"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\/ Vinorelbine Combination in Advanced NSCLC"},"content":{"rendered":"\n<p><strong>Zhejiang Jianfeng Group Co.,\u202fLtd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600668:SHA\">SHA: 600668<\/a>) announced that its subsidiary <strong>Jianfeng Yien Biotechnology<\/strong> has obtained approval from the <strong>National Medical Products Administration (NMPA)<\/strong> to begin a clinical trial of <strong>JFAN\u20111001 Mesylate Capsules<\/strong> in combination with <strong>Vinorelbine Tartrate Soft Capsules<\/strong> for patients with <strong>advanced non\u2011squamous non\u2011small cell lung cancer (NSCLC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-overview\">Product Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>JFAN\u20111001<\/strong> \u2013 a third\u2011generation epidermal growth factor receptor (EGFR) inhibitor designed to target the <strong>T790M secondary mutation<\/strong> that commonly drives resistance to first\u2011 and second\u2011generation EGFR\u2011TKIs.<\/li>\n\n\n\n<li><strong>Indication<\/strong> \u2013 Locally advanced or metastatic <strong>non\u2011squamous NSCLC<\/strong> harboring an <strong>EGFR\u2011T790M<\/strong> mutation.<\/li>\n\n\n\n<li><strong>Combination Rationale<\/strong> \u2013 Pairing JFAN\u20111001 with the microtubule\u2011targeting agent Vinorelbine aims to leverage complementary mechanisms of action, potentially improving disease control in a population with limited treatment options.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-timeline\">Regulatory Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Authority<\/th><th>Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>Oct\u202f2023<\/strong><\/td><td>FDA<\/td><td>Clinical\u2011trial approval granted in the United States<\/td><\/tr><tr><td><strong>15\u202fNov\u202f2025<\/strong><\/td><td>NMPA<\/td><td>Approval granted for Phase\u202fII trial in China (combined JFAN\u20111001\u202f+\u202fVinorelbine)<\/td><\/tr><tr><td><strong>Ongoing<\/strong><\/td><td>NMPA<\/td><td>Phase\u202fII study currently recruiting in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-snapshot\">Clinical Development Snapshot<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fII Enrollment<\/strong> \u2013 Expected to enroll 200\u2011250 patients across major oncology centers in Hangzhou and Shanghai.<\/li>\n\n\n\n<li><strong>Trial Design<\/strong> \u2013 Open\u2011label, single\u2011arm study evaluating overall response rate (ORR) and progression\u2011free survival (PFS) with the combination therapy.<\/li>\n\n\n\n<li><strong>Global Context<\/strong> \u2013 JFAN\u20111001\u2019s U.S. FDA approval in 2023 positioned it as a frontline option for T790M\u2011positive NSCLC, and its Chinese registration now offers a first\u2011in\u2011class targeted therapy to mainland patients.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-strategic-implications\">Market &amp; Strategic Implications<\/h2>\n\n\n\n<p>The <strong>EGFR\u2011T790M<\/strong> mutation accounts for ~50\u202f% of acquired resistance in EGFR\u2011mutant NSCLC. Current treatment options in China are limited to <strong>re\u2011biopsy\u2011guided osimertinib<\/strong> rechallenge or chemotherapy alone, leaving a sizable unmet need. Jianfeng\u2019s combination strategy anticipates a 12\u2011month overall survival (OS) advantage of <strong>10\u201315\u202f%<\/strong> over monotherapy, aligning with industry benchmarks for novel dual\u2011modality regimens.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This briefing contains forward\u2011looking statements concerning regulatory approvals, trial conduct, and commercial prospects. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600668_20251115_L1AX.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600668_20251115_L1AX.\"><\/object><a id=\"wp-block-file--media-227048b0-0bce-463a-b314-2ad512815962\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600668_20251115_L1AX.pdf\">600668_20251115_L1AX<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600668_20251115_L1AX.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-227048b0-0bce-463a-b314-2ad512815962\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang Jianfeng Group Co.,\u202fLtd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48466,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,2044,2043],"class_list":["post-48464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-jianfeng-group","tag-sha-600668"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\/ Vinorelbine Combination in Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Jianfeng Group Co.,\u202fLtd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained approval from the National Medical Products Administration (NMPA) to begin a clinical trial of JFAN\u20111001 Mesylate Capsules in combination with Vinorelbine Tartrate Soft Capsules for patients with advanced non\u2011squamous non\u2011small cell lung cancer (NSCLC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48464\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\/ Vinorelbine Combination in Advanced NSCLC\" \/>\n<meta property=\"og:description\" content=\"Zhejiang Jianfeng Group Co.,\u202fLtd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained approval from the National Medical Products Administration (NMPA) to begin a clinical trial of JFAN\u20111001 Mesylate Capsules in combination with Vinorelbine Tartrate Soft Capsules for patients with advanced non\u2011squamous non\u2011small cell lung cancer (NSCLC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48464\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T11:26:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-17T11:26:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\\\/ Vinorelbine Combination in Advanced NSCLC\",\"datePublished\":\"2025-11-17T11:26:37+00:00\",\"dateModified\":\"2025-11-17T11:26:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464\"},\"wordCount\":339,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1702-1.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Jianfeng Group\",\"SHA: 600668\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48464#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48464\",\"name\":\"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\\\/ Vinorelbine Combination in Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1702-1.webp\",\"datePublished\":\"2025-11-17T11:26:37+00:00\",\"dateModified\":\"2025-11-17T11:26:38+00:00\",\"description\":\"Zhejiang Jianfeng Group Co.,\u202fLtd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained approval from the National Medical Products Administration (NMPA) to begin a clinical trial of JFAN\u20111001 Mesylate Capsules in combination with Vinorelbine Tartrate Soft Capsules for patients with advanced non\u2011squamous non\u2011small cell lung cancer (NSCLC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48464\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1702-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1702-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\\\/ Vinorelbine Combination in Advanced NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48464#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\\\/ Vinorelbine Combination in Advanced NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\/ Vinorelbine Combination in Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang Jianfeng Group Co.,\u202fLtd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained approval from the National Medical Products Administration (NMPA) to begin a clinical trial of JFAN\u20111001 Mesylate Capsules in combination with Vinorelbine Tartrate Soft Capsules for patients with advanced non\u2011squamous non\u2011small cell lung cancer (NSCLC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48464","og_locale":"en_US","og_type":"article","og_title":"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\/ Vinorelbine Combination in Advanced NSCLC","og_description":"Zhejiang Jianfeng Group Co.,\u202fLtd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained approval from the National Medical Products Administration (NMPA) to begin a clinical trial of JFAN\u20111001 Mesylate Capsules in combination with Vinorelbine Tartrate Soft Capsules for patients with advanced non\u2011squamous non\u2011small cell lung cancer (NSCLC).","og_url":"https:\/\/flcube.com\/?p=48464","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-17T11:26:37+00:00","article_modified_time":"2025-11-17T11:26:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48464#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48464"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\/ Vinorelbine Combination in Advanced NSCLC","datePublished":"2025-11-17T11:26:37+00:00","dateModified":"2025-11-17T11:26:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48464"},"wordCount":339,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48464#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702-1.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Jianfeng Group","SHA: 600668"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48464#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48464","url":"https:\/\/flcube.com\/?p=48464","name":"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\/ Vinorelbine Combination in Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48464#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48464#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702-1.webp","datePublished":"2025-11-17T11:26:37+00:00","dateModified":"2025-11-17T11:26:38+00:00","description":"Zhejiang Jianfeng Group Co.,\u202fLtd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained approval from the National Medical Products Administration (NMPA) to begin a clinical trial of JFAN\u20111001 Mesylate Capsules in combination with Vinorelbine Tartrate Soft Capsules for patients with advanced non\u2011squamous non\u2011small cell lung cancer (NSCLC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48464#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48464"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48464#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702-1.webp","width":1080,"height":608,"caption":"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\/ Vinorelbine Combination in Advanced NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48464#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhejiang Jianfeng Group Secures NMPA Approval for JFAN\u20111001\/ Vinorelbine Combination in Advanced NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48464"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48464\/revisions"}],"predecessor-version":[{"id":48467,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48464\/revisions\/48467"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48466"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}